SE OF INJECTABLE FORMS OF HYALURONIC ACID AND PLATELET RICH FIBRIN IN THE TREATMENT OF GUM LOSS IN BETWEEN TWO TEETH
Not Applicable
- Conditions
- Health Condition 1: K053- Chronic periodontitis
- Registration Number
- CTRI/2020/12/029924
- Lead Sponsor
- Institute of Dental Studies and Technologies
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
•Patients in good general health
•Patients with at least one Type I or II (Norland and Tarnowâ??s classification)7 deficient papilla in anterior region
•Well aligned maxillary teeth, no spacing, no crowding or intrusion or extrusion.
Exclusion Criteria
•Pregnant and lactating mothers
•History of tobacco consumption.
•History of taking any medications which are known to increase the risk of gingival hyperplasia.
•Any artificial crown, proximal cervical restoration or abrasion of maxillary anterior teeth.
•Any known allergy with hyaluronic acid
•Patients with history of traumatic oral hygiene measures or periodontal surgeries over the last 6 months at the area of interest
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 2.Clinical measurement: distance from the contact point (CP) to papillary tip using the prepared stent <br/ ><br>3.Photographic measurement: <br/ ><br>4.Radiographic measurement. <br/ ><br> The following distances will be measured <br/ ><br>a.Distance from CP to crest of the bone (BC) <br/ ><br>b.Interdental width at the level of facial CEJ <br/ ><br>Timepoint: follow up at 15th day, 1, 2, 3,4,5,6 months and the clinical and photographic parameters will be re-recorded
- Secondary Outcome Measures
Name Time Method 1.A questionnaire for assessment of patientâ??s response including questions regarding patientâ??s assessment of black triangleTimepoint: First day of treatment and after 6 months